{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000595","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.465645+00:00","generated_at":"2026-06-16T21:31:34.772486+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Arcturus Therapeutics enters $50M revolving credit facility with Wells Fargo","bullets":["Credit agreement with Wells Fargo for $50M revolving line; two-year term, renewable annually.","Borrowings bear interest at SOFR +1.00%; default rate +2.00%.","No prepayment penalty; collateral of $55M in cash pledged.","Commitment fee of 0.25% of loan amount for each renewal."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000595","json":"https://secwatch.observer/filing/0001193805-23-000595.json","markdown":"https://secwatch.observer/filing/0001193805-23-000595.md","text":"https://secwatch.observer/filing/0001193805-23-000595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000595/0001193805-23-000595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000595/e618524_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T21:31:34.772486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67fb4364d0b25e353fa16083783bb6142154f6f3","claim":"Arcturus Therapeutics Holdings Inc. incurred revolving credit of $50 million revolving credit line with Wells Fargo Bank, National Association at 1.00% above either the Daily Simple SOFR or Term SOFR maturing two years.","evidence_excerpt":"On April 21, 2023, Arcturus Therapeutics, Inc. (“Borrower”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc. (the “Company”, and together with Borrower, “Arcturus”), entered into a credit agreement (the “Credit Agreement”) Wells Fargo Bank, National Association (“Wells Fargo”) whereby Wells Fargo will make a $50 million revolving credit line available to Arcturus (the “Loan”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523000595/0001193805-23-000595-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$50 million revolving credit line"},{"label":"Counterparty","value":"Wells Fargo Bank, National Association"},{"label":"Rate","value":"1.00% above either the Daily Simple SOFR or Term SOFR"},{"label":"Maturity","value":"two years"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}